Intestinal cyptosporidiosis in HIV infected children;Criptoporidiosis intestinal el niños con HIV/SIDA

Medicina

Volumn 68, Issue 3, 2008, Pages 213-218

  Barboni, Graciela ^a   Candi, Marcela ^a   Villace, Maria Ines ^a   Leonardelli, Arceli ^a   Balbaryski, Jeanette ^a,b   Gaddi, Eduardo ^a  

^a HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^b NONE   (Argentina)

Author keywords

Crytosporidiosis; HIV in children

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIPARASITIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CHRONIC DIARRHEA; CLINICAL ARTICLE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE DURATION; ELECTROLYTE DISTURBANCE; EOSINOPHILIA; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INTESTINE INFECTION; INTESTINE PARASITE; RECURRENT DISEASE; VIRUS LOAD; AIDS RELATED COMPLEX; ANIMAL; ARGENTINA; EVALUATION; IMMUNE DEFICIENCY; PARASITOLOGY; PRESCHOOL CHILD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-HIV AGENTS; ANTIPARASITIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; AZITHROMYCIN; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE;

EID: 47649115254     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mosier DA, Oberst RD. Cryptosporidiosis: a global challenge. Ann N Y Acad Sci 2000; 916: 102-11.
2. Meinhart PL, Casemore DP, Millar KB. Epidemiologic aspects of human cryptosporidiosis and the role of waterbome transmission. Epidemiol Rev 1996; 18: 118-36.
3. Current WL, García LS. Cryptosporidiosis. Clin Microbiol Rev 1991; 4: 325-58.
4. Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis 1997; 3: 51-7.
5. Clark DP. New insights into human cryptosporidiosis. Clin Microbiol Rev 1999; 12: 554-63.
6. Colford JM Jr, Tager IB, Hirozawa AM, Lemp GF, Aragon T, Petersen C. Cryptosporidiosis among patients infected with human immunodeficiency virus: factors related to symptomatic infection and survival. Am J Epidemiol 1996: 144: 807-16.
7. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. Clin Infec Dis 2005; 40: 131-235.
8. Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N Engl J Med 2002; 346: 1723-31.
9. Chen XM, LaRusso NF. Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells. Gastroenterology 2000; 118: 368-79.
10. Chen XM, Huang BQ, Splinter PL,et al. Cdc42 and the actin-related protein/neural Wiskott-Aldrich syndrome protein network mediate cellular invasion by Cryptosporidium parvum. Infect Immun 2004; 72: 3 011-21.
11. Chen XM, Splinter PL, Tietz PS, Huang BQ, Billadeau DD, LaRusso NF. Phosphatidylinositol 3-kinase and frabin mediate Cryptosporidium parvum cellular invasion via activation of Cdc42. J Biol Chem 2004; 279: 31671-78.
12. Chen XM, O'Hara SP, Huang BQ, Splinter PL, Nelson JB, LaRusso NF. Localized glucose and water influx facilitates Cryptosporidium parvum cellular invasion by means of modulation of host-cell membrane protrusion. Proc Natl Acad Sci USA 2005; 102: 6338-43.
13. Forney JR, DeWald DB, Yang S, Speer CA, Healey MC. A role for host phosphoinositide 3-kinase and cytoskeletal remodelling during Cryptosporidium parvum infection. Infect Immun 1999; 67: 844-52.
14. Simao Ferreira M, Borges AS.Some aspects of protozoan infections in immunocompromised patients. A review. Mem Inst Oswaldo Cruz 2000; 97: 443-57.
15. Chen XM, O'Hara SP, Nelson JB, et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-κB. J Immunol 2005; 175: 7447-56.
16. McDonald V, Smith B, Robinson H, Bancroft G. Host immune responses against Cryptosporidium. Contrib Microbiol 2000; 6: 75-91.
17. Chapppell CL, Okhuysen PC.Cryptosporidiosis. Curr Opin Infect Dis 2002; 15:523-27.
18. Barlett J, Belitsos P, Sears C. AIDS enteropathy. Clin Infect Dis 1992; 15: 726-35.
19. Kartalija M, Sande MA. Diarrhea and AIDS in the era of highly active antiretroviral therapy. Clin Infect Dis 1999; 28: 701-7.
20. Farthing MJ. Clinical aspects of human cryptosporidiosis. Contrib Microbiol 2000; 6: 50-74.
21. CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: 1-10.
22. Saredi N, Bava J. Cryptosporidiosis in pediatric patients. Rev Inst Med Trop S Paulo 1998; 40: 197-200.
23. Theodos CM. Innate and cell-mediated immune responses to Cryptosporidium parvum. Adv Parasitol 1998; 40:87-119.
24. Riggs MW. Recent advances in cryptosporidiosis: the immune response. Microbes Infect 2002; 4: 1067-80.
25. Cordell RL, Thor PM, Addis DG, et al.Impact of a massive waterborne cryptosporìdiosis outbreak on child care facilities in metropolitan Milwaukee, Wisconsin. Pediatr Infect Dis J 1997; 16: 639-44.
26. Siuffi M, Angulo M, Velasco CA, López P, Dueñas V H, Rojas C.Relación entre los niveles de carga viral y los niveles de linfocitos CD4 en el diagnóstico de Cryptosporidium spp. en heces de niños de la Clínica Pediátrica de HIV/Sida del Hospital Universitario del Valle, Cali, Colombia. Colomb Med 2006; 37: 15-20.
27. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200: 749-59.
28. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007; 15: 114-17.
29. Schmidt W, Wahnschaffe U, Schäfer M, et al. Rapid increase of mucosal CD4 T cells followed by clearence of intestinal cryptosporidiosis in an AIDS patient receiving high active antiretroviral theraphy. Gastroenterology 2001; 120: 984-7.
30. Okhuysen PC, Robinson P, Nguyen MT, et al. Jejunal cytokine response in AIDS patients with chronic cryptosporidiosis and during immune reconstitution. AIDS 2001; 15: 802-4.
31. Maggi P, Larocca AM, Ladisa N, et al. Opportunistic parasitic infections of the intestinal tract in the era of highly active antiretroviral theraphy; is the CD4 count so important? Clin Infect Dis 2001; 33: 1609-11.
32. Le Moing V, Bissuel F, Costagliola D, et al. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS 1998; 12: 1395-7.
33. Carr A, Marriott D, Field A, Vasak E. Cooper DA. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral theraphy. Lancet 1998; 351: 256-61.
34. Barboni G, Cantisano C, Gaddi E, et al. Enteric infection caused by Cryptosporidium parvum in HIV-1 infected children. The 1st IAS Conference on HIV Pathogenesis and Treatment. 2001; abstract 712: 294.
35. Mele R, Gómez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int J Parasitol 2003; 33: 757-64.
36. Romagnani S. The Th1/Th2 paradigm.Immunol Today 1997; 18: 263-6.
37. Bentwich Z, Kalinkovich A, Weisman Z, Grossman Z. Immune activation in the context of HIV infection. Clin Exp Immunol 1998; 11: 1-2.